Pregnancy outcomes following exposure to abatacept during pregnancy
Under a Creative Commons license
open access
Keywords
Pregnancy
Abatacept
Exposure
Congenital anomalies
Biological disease-modifying antirheumatic drugs
Abbreviations
DMARD
disease-modifying antirheumatic drug
FDA
Food and Drug Administration
MADCF
Metropolitan Atlanta Congenital Defects Program
MMF
mycophenolate mofetil
MMS
mycophenolate sodium
MTX
methotrexate
OTIS
Organization of Teratology Information Specialists
RA
rheumatoid arthritis
RCT
randomized controlled trial
TNF
tumor necrosis factor
Cited by (0)
This study was sponsored by Bristol-Myers Squibb.
Competing interests: Laura Ray, Sudha Vemuri, and Teresa A. Simon are employees and stockholders of Bristol-Myers Squibb. Monica Kumar is a former employee and stockholder of Bristol-Myers Squibb and currently an employee of Sanofi US.
- 1
Present address: Sanofi US, Bridgewater, NJ.
Copyright © 2015 The Authors. Published by Elsevier Inc.